Beyond Biotech - the podcast from Labiotech
di Labiotech
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
Informazioni su questo podcast
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodi
I 20 episodi più recenti su 221
- Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) · 35 min · Episodio 221Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and…
- GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3) · 28 min · Episodio 220Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and…
- The next big shake-up in the GLP-1 market? (Part 1 of 3) · 36 min · Episodio 219Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and…
- Saudi Arabia's biotech momentum: inside RGMBS 2026 · 34 min · Episodio 218Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit. This September…
- How Flagship's Valo is reshaping AI drug discovery with human data · 36 min · Episodio 217AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of…
- Theialife’s race to bring a childhood myopia treatment to market · 44 min · Episodio 216By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision…
- The best biotech conversations you missed this summer · 40 min · Episodio 215Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from…
- Rewriting the rules of genetic medicine with tRNA therapeutics · 31 min · Episodio 214Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each…
- How Evox Therapeutics is targeting CNS diseases with exosomes · 31 min · Episodio 213Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced…
- BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech · 34 min · Episodio 212Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take…
- Beyond biology: Nanobiotix's physics-first approach to cancer · 31 min · Episodio 211What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over…
- How Cancer Research Horizons is building the future of childhood cancer medicines · 43 min · Episodio 210Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to…
- Why Western pharma is sleeping on China's circular RNA revolution · 36 min · Episodio 209RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a…
- Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's · 42 min · Episodio 208Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene…
- This nonprofit is building the ecosystem to cure epidermolysis bullosa · 40 min · Episodio 207Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and…
- How BIO-Europe is expanding beyond dealmaking in 2026 · 25 min · Episodio 206The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry…
- Turning cancer cell dependencies into targeted therapies · 31 min · Episodio 205Today I’m delighted to welcome Andy Parker, CEO of Step Pharma. With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step…
- The first PROTAC is here. What comes next in protein degradation? · 36 min · Episodio 204Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in…
- De-risking neurology drug development with better mouse models · 41 min · Episodio 203Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug…
- BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler · 41 min · Episodio 202This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical…








